Dynavax Technologies Corporation

NasdaqGS DVAX

Dynavax Technologies Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD 22.67 M

Dynavax Technologies Corporation Free Cash Flow is USD 22.67 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -80.75% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Dynavax Technologies Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 117.78 M, a -15.68% change year over year.
Dynavax Technologies Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 139.68 M, a -27.28% change year over year.
Dynavax Technologies Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 192.08 M, a 272.03% change year over year.
Dynavax Technologies Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -111.65 M, a 30.56% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: DVAX

Dynavax Technologies Corporation

CEO	Mr. Ryan Spencer
IPO Date	Feb. 19, 2004
Location	United States
Headquarters	2100 Powell Street
Employees	408
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Key trends

Past 5 years